Clinical trial
Adj TC + Herceptin Early Stage Breast Cancer
NCT00493649 · US Oncology Research, Industry · Completed
Key facts
| NCT number | NCT00493649 |
|---|---|
| Title | Adj TC + Herceptin Early Stage Breast Cancer |
| Official title | Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Taxotere, Cytoxan, Herceptin |
| Enrollment | 493 |
| Start date | Jun 1, 2007 |
| Primary completion | Apr 1, 2013 |
| Completion | Apr 1, 2013 |
| First posted | Jun 28, 2007 |
| Last update posted | Nov 3, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: